Multifocal Motor Neuropathy Treatment News

Advances in Multifocal Motor Neuropathy (MMN) Treatment: A Sneak Peek to 2025

Multifocal Motor Neuropathy (MMN) is a rare chronic autoimmune disorder that selectively affects the motor nerves, with progressive muscle weakness but no sensory loss. Traditionally, high-dose intravenous immunoglobulin (IVIg) has been the only approved therapy, but advances in 2025 are offering patients renewed hope.

???? Promising Clinical Trials and New Therapies
Empasiprubart: A Game-Changer
Empasiprubart, a novel treatment developed by argenx, has shown significant promise in the management of MMN. Results from the Phase 2 ARDA study indicated that empasiprubart reduced the risk for retreatment with IVIg by 91% versus a placebo. Patients also experienced gain in grip strength and muscle strength and increased day functioning. The treatment was well tolerated, with the majority of effects being mild or moderate. At present, a Phase 3 trial, the EMPASSION trial, is ongoing to further assess empasiprubart’s safety and efficacy relative to IVIg .
Facebook
+5
GlobeNewswire
+5
gb-scidp.org
+5
gb-scidp.org

DNTH103: A New Candidate Under Investigation
Dianthus Therapeutics has initiated a Phase 2 clinical trial of DNTH103, a novel MMN treatment. The trial will assess the safety, tolerability, and efficacy of DNTH103 in 36 patients. Safety and tolerability will be the main outcomes, with secondary outcomes being time to IVIg retreatment, time to relapse, and increases in muscle and grip strength. Early results will be known in the second half of 2026.
WSJ

???? FDA-Approved Treatments and Research Underway
While current treatment for MMN is high-dose IVIg, it doesn’t work for every patient. The emergence of treatments like empasiprubart and DNTH103 represents a new direction towards more targeted treatments. The developments are part of a push to learn more about MMN’s mechanisms and discover more effective treatments.
Euronext Live
+1
argenx
+1
WSJ
+2
GlobeNewswire
+2
gb-scidp.org
+2

???? Raising Awareness and Support
GBS|CIDP Foundation International has announced January 2025 as MMN Awareness Month with a goal to educate the public regarding this illness. Activities include fundraising, educational webinars, and community outreach programs. All these activities are crucial in creating awareness and supporting research.
PR Newswire
+5
gbstroposed.org
+5
gbstroposed.org
+5

???? Access to Treatment and Financial Assistance
In recognition of the expense of MMN treatment, the National Organization for Rare Disorders (NORD) has launched a Patient Assistance Program. The program offers financial assistance to qualified patients to offset out-of-pocket medical costs related to MMN treatment. Patients can apply online at NORD or contact their support staff for additional information.